Five things for pharma marketers to know: Monday, March 27, 2017

1. Alexion Pharmaceuticals appointed Ludwig Hantson, former CEO of Baxalta, as its new CEO. He assumes responsibilities from interim CEO David Brennan. The appointment comes after a number of executive departures following an investigation into the company's sales practices. (Reuters

2. The U.S. dollar dropped to a four-month low today after President Trump's failure to pass the GOP-backed American Health Care Act. The dip is being interpreted as a sign that investors are skeptical about whether he can fulfill other campaign promises, such as tax reform. (AP

3. The European Medicines Agency recommended that more than 300 generic drug approvals and applications by India's Micro Therapeutic Research Labs be suspended due to "misrepresentation of study data and deficiencies in documentation and data handling." The European Commission will make a final decision on the recommendation that will apply to all countries in the European Union. (Reuters

4. Patients using telehealth services don't necessarily save costs vis-a-vis patients who see doctors in person, because 88% of telehealth interactions are by people who would avoid in-person visits if telehealth was unavailable, a study found. (NPR

5. ICYMI: Teva Pharmaceutical Industries plans to cut jobs and expenses in an effort to resolve growing debt after a series of acquisitions. The company snapped up Allergan's generic business for $40.5 billion last August. (Bloomberg)